Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint Pharmaceuticals, Inc. - Common Stock (NQ:EYPT)

12.21 +0.48 (+4.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EyePoint Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Gold Down Over 2%; US Factory Orders Fall In October
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Monday. The Dow traded down 0.36% to 36,116.18 while the NASDAQ fell 1.19% to 14,134.99. The S&P 500... 
Via Benzinga
Topics Stocks
Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today?
EyePoint Pharmaceuticals stock is rising higher with heavy trading of EYPT on Monday after posting positive results from a clinical trial. 
Via InvestorPlace
Nasdaq Down Over 100 Points; Alaska Air To Acquire Hawaiian Airlines
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 100 points on Monday. Following the market opening Monday, the Dow traded down 0.13% to 36,198.88 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Why Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Expert Ratings for EyePoint Pharmaceuticals
 
Via Benzinga
Where EyePoint Pharmaceuticals Stands With Analysts
 
Via Benzinga
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing. 
Via InvestorPlace
Mizuho's Top Stock Picks For November Revealed
As trading for November begins, Mizuho recommends a few stocks for investors to consider. 
Via Benzinga
Why Is Vision Disorder-Focused EyePoint Pharmaceuticals Stock Trading Higher Today?
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) reported Q3 revenues of $15.20 million, up from $10 million a year ago and beating  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Shares of EyePoint Pharmaceuticals Were Rising Monday
The company reported positive trial data for its lead therapy to treat two different eye conditions. 
Via The Motley Fool
What 6 Analyst Ratings Have To Say About EyePoint Pharmaceuticals
 
Via Benzinga
5 Analysts Have This to Say About EyePoint Pharmaceuticals
 
Via Benzinga
EyePoint Pharmaceuticals: Q1 Earnings Insights
 
Via Benzinga
Why's Going On With EyePoint Pharmaceuticals Stock Today?
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced interim masked safety data for its lead product candidate EYP-1901 from its ongoing Phase 2 PAVIA trial of EYP-1901 as a potential nine-month... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Are EyePoint Pharmaceuticals Shares Trading Higher Today
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) shares are trading higher after the company appointed Jay Duker as chief executive officer, transitioning from his most recent role as chief operating  
Via Benzinga
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
 
Via Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Alimera Sciences (ALIM) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (EYPT). 
Via InvestorPlace
EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has agreed to sell Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences Inc (NASDAQ: ALIM).  
Via Benzinga
Why EyePoint Pharmaceuticals Shares Are Shooting Higher Today
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) reported Q1 revenues of $7.68 million, down from $9.3 million a year ago but slightly  
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
Super Micro Computer, Garrett Motion, Rackspace Technology And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Nasdaq Edges Higher; Procter & Gamble Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite edging higher on Friday. The Dow traded down 0.06% to 33,765.47 while the NASDAQ rose 0.02% to 12,062.18. The S&P 500, also... 
Via Benzinga
EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equities by Percentage Gain on 4/21
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.